for most AIMs subtypes. Inhaled glucocorticoids were the only subtype to show a trend with increased cumulative dose (p<0.001).
INTRODUCTION AND OBJECTIVES: Both prostate cancer (PC) screening and management are highly controversial topics within the medical community. Numerous recommendations have been published during the last years and their cumulative influence on diagnosis and initial management of PC are unknown. Therefore, the aim of the current study was to investigate trends in diagnosis and initial management of localized PC at the population level within the province of Ontario.
METHODS: We used the Ontario Cancer Registry to identify incident cases of localized prostate cancer between January 2011 and October 2016. Cases were linked to health-administrative databases to determine the proportion of patients undergoing either radical prostatectomy (RP), radiation therapy (RT), active surveillance (AS) or watchful waiting (WW). Furthermore, we determined the fraction of low-risk patients (d'Amico risk stratification) among each management modality. Data were aggregated at a monthly level and descriptively analyzed as time series.
RESULTS: During the accrual windows of 70 months, 33128 index cases were identified. We detected a clear change in the slope of the linear trend in monthly PC incidence (see Figure 1 ; averaged over first year of observation period: 581; averaged over last year of observation period: 482). The evaluation of the initial management strategies demonstrated a decrease in RP (34.8% to 30.8%), an increase in RT (21.4% to 26.5%) and a mostly stable proportion of patients initially undergoing AS or WW. The fraction of low-risk patients among the definitive treatments (RP and RT) steadily decreased since 2011 (RP: 18.1%; RT: 13.4%) and currently plateaus at a very low level (RP: 6.0%; RT: 2.7%).
CONCLUSIONS: This population-wide study evaluated trends in diagnosis and initial management of localized PC and found a clear decrease in diagnosis that temporally aligns with the publication of the United States Preventive Services Task Force Recommendation in 2012 not to screen patients with the prostatespecific antigen test. We further noticed an increase in RT at the cost of a decrease in RP. In concordance with most of the current recommendations, patients presenting with low-risk disease are more and more spared from definitive treatment.
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INTRODUCTION AND OBJECTIVES: Prostate cancer (PCa) is increasingly recognized as a part of hereditary cancer syndromes (HCS) with implications for cascade genetic testing (CGT) of men with
PCa in these families. However, race-specific rates of HCS in probands presenting for inherited cancer assessment who report a family history (FHx) of PCa is not known and has implications for CGT of men with PCa.
METHODS: A prospectively maintained genetic testing database at a tertiary care cancer genetics program was queried for all probands reporting a PCa FHx. Pedigrees were analyzed for three HCS linked with PCa: hereditary breast and ovarian syndrome (HBOC), classic Hereditary PCa (HPC), and Lynch syndrome (LS). Associations between HCS and race were evaluated using Fisher's exact test. Each HCS was evaluated for potential genetic link to the male relative with PCa and associations with race were tested using Fisher's exact test.
RESULTS: 345 probands met inclusion criteria: 53 African Americans (AA), 292 Caucasians (Wh), 74.5% female. Proband cancer diagnoses included breast (43.2%), prostate (12.8%), pancreatic (3.8%), ovarian (3.2%), and colorectal (2.9%). Overall, 63.8% of probands met criteria for ! 1 HCS based on personal and FHx. Male relatives with PCa in these families with potential genetic link to HCS were found in 75.5% AA families and 61.6% Wh families. HBOC was identified in a higher percentage of AA families with a potentially-linked male relative with PCa compared to Wh families (69.8% vs. 52.4%, respectively; p[0.051). Among probands with HCS potentially linked to PCa (n [ 169), 19.5% were found to carry a genetic mutation in a cancer risk gene (17.9% AA and 19.9% Wh). BRCA1/2 mutations accounted for all mutations identified in AA probands and 66.7% of Wh probands.
CONCLUSIONS: A significant percentage of patients who present for inherited cancer assessment report a FHx of PCa potentially linked with a HCS. Importantly, AA probands with a PCa FHx have comparable rates of HCS as Wh probands, with potentially higher rates of HBOC in AA families accounted for by BRCA mutations. Cascade Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e597
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